Assessment of circulating biomarkers in a rat model of doxorubicin-induced cardiotoxicity

Authors

  • Emilia ANCA Doctoral School of Integrative Biology, Faculty of Biology and Geology, Babeș-Bolyai University, Cluj-Napoca, Romania https://orcid.org/0000-0002-1446-3730
  • Francesca SABĂU Doctoral School of Integrative Biology, Faculty of Biology and Geology, Babeș-Bolyai University, Cluj-Napoca, Romania https://orcid.org/0009-0002-1532-4203
  • Andreea VĂDAN Doctoral School of Integrative Biology, Faculty of Biology and Geology, Babeș-Bolyai University, Cluj-Napoca, Romania
  • Mădălina MARINESCU Faculty of Biology and Geology and Center of Systems Biology, Biodiversity and Bioresources, Babeș-Bolyai University, Cluj-Napoca, Romania
  • Emilia LICĂRETE Faculty of Biology and Geology and Center of Systems Biology, Biodiversity and Bioresources, Babeș-Bolyai University, Cluj-Napoca, Romania https://orcid.org/0000-0003-1190-6003
  • Corina ROȘIORU Faculty of Biology and Geology and Center of Systems Biology, Biodiversity and Bioresources, Babeș-Bolyai University, Cluj-Napoca, Romania https://orcid.org/0000-0003-2613-2055
  • Anca Daniela STOICA Faculty of Biology and Geology and Center of Systems Biology, Biodiversity and Bioresources, Babeș-Bolyai University, Cluj-Napoca, Romania https://orcid.org/0000-0002-7510-5793
  • Camelia DOBRE Faculty of Biology and Geology and Center of Systems Biology, Biodiversity and Bioresources, Babeș-Bolyai University, Cluj-Napoca, Romania. Corresponding author: camelia.dobre@ubbcluj.ro
  • Manuela Cristina BANCIU Doctoral School of Integrative Biology, Faculty of Biology and Geology; Faculty of Biology and Geology and Center of Systems Biology, Biodiversity and Bioresources, Babeș-Bolyai University, Cluj-Napoca, Romania https://orcid.org/0000-0003-2556-4008

DOI:

https://doi.org/10.24193/subbbiol.2024.2.01

Keywords:

CTRCD, CTOX, DOX, doxorubicin, circulating biomarkers

Abstract

The number of cancer survivors is increasing as cancer therapies become more and more effective. As a consequence, cardio-oncology is nowadays more shifted towards detecting and treating conditions such as CTOX, which refers to heart damage as a result of cancer treatment. Currently, a standardized way of evaluating and monitoring CTOX does not exist, and patients undergo nonspecific and lengthy tests, so they are often diagnosed when heart damage is irreversible. Thus, we assessed a panel of circulating biomarkers that can be used to monitor time-dependent changes in Wistar rats treated with conventional or liposomal DOX. After validation this panel might be applied in clinics to enhance accuracy of screening patients undergoing DOX-based therapy approaches.

Article history: Received 07 November 2024; Revised 04 December 2024;
Accepted 04 December 2024; Available online 10 December 2024

References

Abdulkareem Aljumaily, S. A., Demir, M., Elbe, H., Yigitturk, G., Bicer, Y. & Altinoz, E. (2021). Antioxidant, anti-inflammatory, and anti-apoptotic effects of crocin against doxorubicin-induced myocardial toxicity in rats. Environ Sci Pollut R, 28(46), 65802-65813. https://doi.org/10.1007/s11356-021-15409-w

Ahmad, A., Imran, M. & Ahsan, H. (2023). Biomarkers as biomedical bioindicators: approaches and techniques for the detection, analysis, and validation of novel biomarkers of diseases. Pharmaceutics 15(6), 1630. https://doi.org/10.3390/pharmaceutics15061630

Arunachalam, S., Tirupathi Pichiah, P. B. & Achiraman, S. (2013). Doxorubicin treatment inhibits PPARγ and may induce lipotoxicity by mimicking a type 2 diabetes-like condition in rodent models. FEBS Lett, 587(2), 105-10. https://doi.org/10.1016/j.febslet.2012.11.019

Belger, C., Abrahams, C., Imamdin, A. & Lecour, S. (2024). Doxorubicin-induced cardiotoxicity and risk factors. Int J Cardiol Heart Vasc, 50, 101332. https://doi.org/10.1016/j.ijcha.2023.101332

Bhatnagar, R., Dixit, N. M., Yang, E. H. & Sallam, T. (2022). Cancer therapy’s impact on lipid metabolism: mechanisms and future avenues. In Front Cardiovasc Med, 9, 925816. https://doi.org/10.3389/fcvm.2022.925816

Bisoc, A., Ciurescu, D., Rǎdoi, M., Tântu, M. M., Rogozea, L., Sweidan, A. J. & Bota, D. A. (2020). elevations in high-sensitive cardiac troponin t and n-terminal prohormone brain natriuretic peptide levels in the serum can predict the development of anthracycline-induced cardiomyopathy. Am J Ther, 27(2), e142-e150. https://doi.org/10.1097/MJT.0000000000000930

Bloom, M. W., Hamo, C. E., Cardinale, D., Ky, B., Nohria, A., Baer, L., Skopicki, H., Lenihan, D. J., Gheorghiade, M., Lyon, A. R. & Butler, J. (2016). Cancer therapy-related cardiac dysfunction and heart failure: part 1: definitions, pathophysiology, risk factors, and imaging. Circ Heart Fail, 9(1), e002661. https://doi.org/10.1161/CIRCHEARTFAILURE.115.002661

Cardinale, D., Iacopo, F. & Cipolla, C. M. (2020). cardiotoxicity of anthracyclines. In Front Cardiovasc Med, 7, 26. https://doi.org/10.3389/fcvm.2020.00026

Dattani, S., Spooner, F., Ritchie, H. & Roser, M. causes of death. Our World in Data. (2023) [Accessed 28 August 2024] https://ourworldindata.org/causes-of-death

de Barros Wanderley, M. R., Ávila, M. S., Fernandes-Silva, M. M., das Dores Cruz, F., Brandão, S. M. G., Rigaud, V. O. C., Hajjar, L. A., Filho, R. K., Cunha-Neto, E., Bocchi, E. A. & Ayub-Ferreira, S. M. (2022). Plasma biomarkers reflecting high oxidative stress in the prediction of myocardial injury due to anthracycline chemotherapy and the effect of carvedilol: insights from the CECCY Trial. Oncotarget, 13(1). https://doi.org/10.18632/ONCOTARGET.28182

Demissei, B. G., Hubbard, R. A., Zhang, L., Smith, A. M., Sheline, K., McDonald, C., Narayan, V., Domchek, S. M., DeMichele, A., Shah, P., Clark, A. S., Fox, K., Matro, J., Bradbury, A. R., Knollman, H., Getz, K. D., Armenian, S. H., Januzzi, J. L., Tang, W. H. W., … Ky, B. (2020). Changes in cardiovascular biomarkers with breast cancer therapy and associations with cardiac dysfunction. J Am Heart Assoc, 9(2), 214-223. https://doi.org/10.1161/JAHA.119.014708

Dong, Y., Wu, Q. & Hu, C. (2022). Early Predictive Value of NT-proBNP Combined

With Echocardiography in anthracyclines induced cardiotoxicity. Front Surg, 9, 898172. https://doi.org/10.3389/fsurg.2022.898172

Franco, Y. L., Vaidya, T. R. & Ait-Oudhia, S. (2018). Anticancer and cardio-protective effects of liposomal doxorubicin in the treatment of breast cancer. Breast Cancer: Target (Dove Med Press), 10, 131–141. https://doi.org/10.2147/BCTT.S170239

Huang, J., Wu, R., Chen, L., Yang, Z., Yan, D. & Li, M. (2022). Understanding anthracycline cardiotoxicity from mitochondrial aspect. Front Pharmacol, 13, 811406. https://doi.org/10.3389/fphar.2022.811406

Kumfu, S., Chattipakorn, S. C. & Chattipakorn, N. (2022). Iron overload cardiomyopathy: using the latest evidence to inform future applications. Exp Biol Med 247(7). https://doi.org/10.1177/15353702221076397

McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., Cleland, J. G. F., Crespo-Leiro, M. G., Farmakis, D., Gilard, M., Heymans, S., Hoes, A. W., Jaarsma, T., Jankowska, E. A., Lainscak, M., … Skibelund, A. K. (2024). 2023 Focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail, 26(1), 811406. https://doi.org/10.1002/ejhf.3024

Morelli, M. B., Bongiovanni, C., Da Pra, S., Miano, C., Sacchi, F., Lauriola, M. & D’Uva, G. (2022). Cardiotoxicity of anticancer drugs: molecular mechanisms and strategies for cardioprotection. Front Cardiovasc Med, 9, 847012. https://doi.org/10.3389/fcvm.2022.847012

Niang, D. G. M., Ka, S., Hendricks, J., Diouf, D., Gaba, F. M., Diouf, A., Diop, M., Mbow, M., Faye, B., Diallo, R. N., Niang, M. D. S., Deme, A., Mbengue, B. & Dieye, A. (2022). Profile of plasma galectin-3 concentrations, inflammatory cytokines levels and lymphocytes status in breast cancer under chemotherapy. Open J Immunol, 12(01). https://doi.org/10.4236/oji.2022.121001

Pagan, L. U., Gomes, M. J., Gatto, M., Mota, G. A. F., Okoshi, K. & Okoshi, M. P. (2022). The role of oxidative stress in the aging heart. Antioxidants, 11(2), 336. https://doi.org/10.3390/antiox11020336

Perez, I. E., Taveras Alam, S., Hernandez, G. A. & Sancassani, R. (2019). Cancer therapy-related cardiac dysfunction: an overview for the clinician. Clin Med Insights Cardiol, 13, 1179546819866445. https://doi.org/10.1177/1179546819866445

Posch, F., Niedrist, T., Glantschnig, T., Firla, S., Moik, F., Kolesnik, E., Wallner, M., Verheyen, N., Jost, P. J., Zirlik, A., Pichler, M., Balic, M. & Rainer, P. P. (2022). Left ventricular ejection fraction and cardiac biomarkers for dynamic prediction of cardiotoxicity in early breast cancer. Front Cardiovasc Med, 9, 933428. https://doi.org/10.3389/fcvm.2022.933428

Rivankar, S. (2014). An overview of doxorubicin formulations in cancer therapy. In J Cancer Res Ther, 10(4), 853-858. https://doi.org/10.4103/0973-1482.139267

Ruggiero, A., De Rosa, G., Rizzo, D., Leo, A., Maurizi, P., De Nisco, A., Vendittelli, F., Zuppi, C., Mordente, A. & Riccardi, R. (2013). Myocardial performance index and biochemical markers for early detection of doxorubicin-induced cardiotoxicity in children with acute lymphoblastic leukaemia. Int J Clin Oncol, 18(5), 927-933. https://doi.org/10.1007/s10147-012-0458-9

Schmidt, M. E., Goldschmidt, S., Hermann, S. & Steindorf, K. (2022). Late effects, long-term problems and unmet needs of cancer survivors. Int J Cancer, 151(8), 1280-1290. https://doi.org/10.1002/ijc.34152

Sesarman, A., Tefas, L., Sylvester, B., Licarete, E., Rauca, V., Luput, L., Patras, L., Banciu, M. & Porfire, A. (2018). Anti-angiogenic and anti-inflammatory effects of long-circulating liposomes co-encapsulating curcumin and doxorubicin on C26 murine colon cancer cells. Pharmacol Rep, 70(2), 331-339. https://doi.org/10.1016/j.pharep.2017.10.004

Shafiq, A., Moore, J., Suleman, A., Faiz, S., Farooq, O., Arshad, A., Tehseen, M., Zafar, A., Ali, S. H., Din, N. U., Loya, A., Siddiqui, N. & Rehman, F. K. (2020). Elevated soluble galectin-3 as a marker of chemotherapy efficacy in breast cancer patients: a prospective study. Int J Breast Cancer, 2020, 4824813. https://doi.org/10.1155/2020/4824813

Sharma, M., Tuaine, J., McLaren, B., Waters, D. L., Black, K., Jones, L. M. & McCormick, S. P. A. (2016). Chemotherapy agents alter plasma lipids in breast cancer patients and show differential effects on lipid metabolism genes in liver cells. PLoS ONE, 11(1), e0148049. https://doi.org/10.1371/journal.pone.0148049

Shinlapawittayatorn, K., Chattipakorn, S. C. & Chattipakorn, N. (2022). The effects of doxorubicin on cardiac calcium homeostasis and contractile function. J Cardiol, 80(2), 125-132. https://doi.org/10.1016/j.jjcc.2022.01.001

Simões, R., Silva, L. M., de Oliveira, A. N., Alves, M. T., Pestana, R. M. C., de Souza, I. D. P., Oliveira, H. H. M., Soares, C. E., Sabino, A. de P. & Gomes, K. B. (2021). identification of clinical and laboratory variables associated with cardiotoxicity events due to doxorubicin in breast cancer patients: a 1-year follow-up study. Cardiovasc Toxicol, 21(2), 106-114. https://doi.org/10.1007/s12012-020-09600-7

Vucic, R. M., Andrejic, O. M., Stokanovic, D., Stoimenov, T. J., McClements, L., Nikolic, V. N., Sreckovic, M., Veselinovic, M., Aleksandric, S., Popadic, V., Zdravkovic, M. & Pavlovic, M. (2023). Galectin-3 as a prognostic biomarker in patients with first acute myocardial infarction without heart failure. Diagnostics, 13(21), 3348. https://doi.org/10.3390/diagnostics13213348

Downloads

Published

2024-12-10

How to Cite

ANCA, E., SABĂU, F., VĂDAN, A., MARINESCU, M., LICĂRETE, E., ROȘIORU, C., … BANCIU, M. C. (2024). Assessment of circulating biomarkers in a rat model of doxorubicin-induced cardiotoxicity. Studia Universitatis Babeș-Bolyai Biologia, 69(2), 7–22. https://doi.org/10.24193/subbbiol.2024.2.01

Issue

Section

Articles